Annual Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Taro Pharmaceutical Industries Ltd.

Pharma Giants' Revenue Battle: Ligand vs. Taro

__timestampLigand Pharmaceuticals IncorporatedTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201464538000759285000
Thursday, January 1, 201571914000862944000
Friday, January 1, 2016108973000950751000
Sunday, January 1, 2017141102000879387000
Monday, January 1, 2018251453000661913000
Tuesday, January 1, 2019120282000669893000
Wednesday, January 1, 2020186419000644769000
Friday, January 1, 2021277133000548970000
Saturday, January 1, 2022196245000561347000
Sunday, January 1, 2023131314000572952000
Monday, January 1, 2024629182000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Pharmaceuticals: Revenue Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Ligand Pharmaceuticals Incorporated and Taro Pharmaceutical Industries Ltd. have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, Taro consistently outperformed Ligand, with revenues peaking at approximately $950 million in 2016, a stark contrast to Ligand's highest revenue of around $277 million in 2021. This represents a revenue ratio where Taro's earnings were often more than three times that of Ligand's. However, both companies faced revenue declines in recent years, with Taro's revenue dropping by about 40% from its peak, while Ligand saw a 53% increase from 2014 to 2021 before a subsequent decline. Notably, 2024 data for Ligand is missing, leaving room for speculation on its future performance. These trends highlight the dynamic nature of the pharmaceutical industry and the varying strategies companies employ to navigate it.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025